The nature of immunological reaction in the peripheral airways of cigarette smokers

Current Respiratory Medicine Reviews

Volumn 3, Issue 2, 2007, Pages 117-127

  Domagala Kulawik, Joanna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Immunity; Lung; Lymphocytes; Macrophages; Neutrophils; Smoking

Indexed keywords

CD11 ANTIGEN; CD14 ANTIGEN; CD71 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE MARKER; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LEUKOCYTE ELASTASE; LYMPHOCYTE RECEPTOR; TOBACCO SMOKE; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY; ANTIGEN PRESENTATION; APOPTOSIS; ASTHMA; ATHEROSCLEROSIS; BRONCHUS MUCOSA; CELL DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DYSPLASIA; EOSINOPHILIA; GRANULOCYTE; HEALTH STATUS; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LEUKOCYTOSIS; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LYMPHOCYTOSIS; MACROPHAGE FUNCTION; METAPLASIA; NEUTROPHILIA; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SMOKING CESSATION; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 34248683269     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339807780599199     Document Type: Review

References (131)

1. Tobacco smoking. European Lung White Book. ERS. 2004; 108-124.
2. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271-80.
3. Smoking and immunity. Lancet 1990; 335: 1561-63.
4. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
5. Hoser G, Domagała-Kulawik J, Droszcz P, Droszcz W, Kawiak J. Lymphocyte subsets differences in smokers and nonsmokers with primary lung cancer: a flow cytometry analysis of bronchoalveolar lavage fluid cells. Med Sci Monit 2003; 9: BR310-315.
6. Domagala- Kulawik J, Hoser G, Droszcz P, Kawiak J, Droszcz W, Chazan R. T-cell subtypes in bronchoalveolar lavage fluid and in peripheral blood from patients with primary lung cancer. Diagn Cytopathol 2001; 25: 208-213.
7. Wright JL, Churg A. A model of tobacco smoke-induced airflow obstruction in the guinea pig. Chest 2002; 121: 188S-91S.
8. Kubo S, Kobayashi M, Masunaga Y, et al. Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs. Eur Respir J 2005; 26(6): 993-1001.
9. Shields PG. Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst 2002; 94: 1435-44.
10. Slama K. Active smoking. In: ERS Ed, Respiratory Epidemiology in Europe. Monograph 15, Vol.5, ERS Journals LTD. 2000; 305-321.
11. Ekberg-Jansson A, Arva E, Nilsson O, Lofdahl CG, Andersson B. A comparison of the expression of lymphocyte activation markers in blood, bronchial biopsies and bronchoalveolar lavage: evidence for an enrichment of activated T lymphocytes in the bronchoalveolar space. Respir Med 1999; 93: 563-70.
12. Uller L, Persson CG, Erjefalt JS. Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both? Trends Pharmacol Sci 2006; 27: 461-6.
13. Visscher DW, Myers JL. Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc 2006; 3: 41-7.
14. Wright JL, Cagle P, Churg A, et al. Diseases of the small airways. Am Rev Respir Dis 1992; 146: 240-262.
15. Shaw RJ, Djukanovic R, Tashkin DP, et al. The role of small airways in lung disease. Respir Med 2002; 96: 67-80.
16. Zielinski J, Bednarek M, Gorecka D, et al. Increasing COPD awareness. Eur Respir J 2006; 27(4): 833-52.
17. Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax 2003; 58: 135-42.
18. Ekberg-Jansson A, Andersson B, Bake B, et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. Respir Med 2001; 95: 363-73.
19. Ekberg-Jansson A, Andersson B, Avra E, Nilsson O, Lofdahl CG. The expression of lymphocyte surface antigens in bronchial biopsies, bronchoalveolar lavage cells and blood cells in healthy smoking and never-smoking men, 60 years old. Respir Med 2000; 94: 264-72.
20. Ekberg-Jansson A, Bake B, Andersson B, Skoogh BE, Lofdahl CG. Respiratory symptoms relate to physiological changes and inflammatory markers reflecting central but not peripheral airways. A study in 60- year-old 'healthy' smokers and never-smokers. Respir Med 2001; 95: 40-47.
21. Behr J, Nowak D. Tobacco smoke and respiratory disease. In: ERS ed, The Impact of Air Pollution on Respiratory Tract. Monograph 21. Vol.7. ERS Journals LTD. 2002; 161-180.
22. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 67-86.
23. Janson C. The effect of passive smoking on respiratory health in children and adults. Int J Tuberc Lung Dis 2004; 8: 510-516.
24. Jaakkola MS, Jaakkola JJ. Assessment of exposure to environmental tobacco smoke. Eur Respir J 1997; 10: 2384-97.
25. Jaakkola MS. Environmental tobacco smoke and respiratory tract. In ERS ed, Respiratory Epidemiology in Europe. Monograph 15. Vol. 5. ERS Journals LDT. 2000; 322-383.
26. Mossman BT, Lounsbury KM, Reddy SP. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am J Respir Cell Mol Biol 2006; 34(6): 666-9.
27. Wallace JM, Oishi JS, Barbers RG, Simmons MS, Tashkin DP. Lymphocytic subpopulation profiles in bronchoalveolar lavage fluid and peripheral blood from tobacco and marijuana smokers. Chest 1994; 105(3): 847-852.
28. Fligiel SE, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest 1997; 112(2): 319-326.
29. Dye JA, Adler KB. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994; 49: 825-34.
30. Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol 2003; 285: L492-L499.
31. Hodge S, Hodge G, Holmes M, Reynolds PN. Apoptosis in COPD. Curr Respir Med Rev 2005; 1: 33-41.
32. Pettersen CA, Adler KB. Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 2002; 121: 142S-50S.
33. Di Stefano A, Caramori G, Ricciardolo FLM, Capelli A, Adcock IM, Donner CF. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overwiew. Clin Exp Allergy 2004; 34: 1156-1167.
34. Terashima T, Klut ME, English D, Hards J, Hogg JC, van Eeden SF. Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung microvessels. Am J Respir Cell Mol Biol 1999; 20: 171-77.
35. Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002; 20: 556-63.
36. Kassirer M, Zeltser D, Prochorov V, et al. Increased expression of the CD11b/CD18 antigen on the surface of peripheral white blood cells in patients with ischemic heart disease: further evidence for smoldering inflammation in patients with atherosclerosis. Am Heart J 1999; 138: 555-59.
37. Gonzalez S, Hards J, van Eeden S, et al. The expression of adhesion molecules in cigarette smoke-induced airways obstruction. Eur Respir J 1996; 9: 1995-2001
38. van Eeden SF, Yeung A, Quinlam K, Hogg JC. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 61-7.
39. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23: 327-33.
40. Barbour SE, Nakashima K, Zhang JB, et al. Tobacco and smoking: environmental factors that modify the host response (immune system) and have an impact on periodontal health. Crit Rev Oral Biol Med 1997; 8: 437-60.
41. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004; 3: 147-59.
42. Barczyk A, Sozańska E, Pierzchała W. Increased levels of epidermal growth factor in the sputum of smoking patients with chronic bronchitis. Int Rev Allergol Clin Immunol 2006; 12: 12-17.
43. Skold CM, Lundahl J, Hallden G, Hallgren M, Eklund A. Chronic smoke exposure alters the phenotype pattern and the metabolic response in human alveolar macrophages. Clin Exp Immunol 1996; 106: 108-13.
44. Kerenyi T, Voss B, Goeckenjan G, Muller KM. Cellular autofluorescent pigment and interstitial fibrosis in smoker's lung. Pathol Res Pract 1992; 188: 925-30.
45. Pons AR, Noguera A, Blanquer D, Sauleda J, Pons J, Agusti AG. Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD. Eur Respir J 2005; 25(4):647-52.
46. Mancini NM, Bene MC, Gerard H, et al. Early effects of short-time cigarette smoking on the human lung: a study of bronchoalveolar lavage fluids. Lung 1993; 171: 277-91.
47. Kong LY, Luster MI, Dixon D, O'Grady J, Rosenthal GJ. Inhibition of lung immunity after intratracheal instillation of benzo(a)pyrene. Am J Respir Crit Care Med 1994; 150: 1123-29.
48. Takeuchi M, Nagai S, Nakajima A, et al. Inhibition of lung natural killer cell activity by smoking: the role of alveolar macrophages. Respiration 2001; 68: 262-67.
49. Yamaguchi E, Itoh A, Furuya K, Miyamoto H, Abe S, Kawakami Y. Release of tumor necrosis factor-alpha from human alveolar macrophages is decreased in smokers. Chest 1993; 103: 479-83.
50. Ohta T, Yamashita N, Maruyama M, Sugiyama E, Kobayashi M. Cigarette smoking decreases interleukin-8 secretion by human alveolar macrophages. Respir Mod 1998; 92: 922-27.
51. Helleday R, Sandstrom T, Stjernberg N. Differences in bronchoalveolar cell response to nitrogen dioxide exposure between smokers and nonsmokers. Eur Respir J 1994; 7: 1213-20.
52. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-688.
53. Larsson L, Szponar B, Pehrson C. Tobacco smoking increases dramatically air concentrations of endotoxin. Indoor Air 2004; 14: 421-4.
54. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987; 42: 241-49.
55. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005; 6: 68.
56. Noakes PS, Hale J, Thomas R, Lane C, Devadason SG, Prescott SL. Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J 2006; 28: 721-9.
57. Umino T, Skold CM, Pirruccello SJ, Spurzem JR, Rennard SI. Two-colour flow-cytometric analysis of pulmonary alveolar macrophages from smokers. Eur Respir J 1999; 13: 894-9.
58. Di Stefano A, Caramori G, Capelli A, et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 78-85.
59. Lensmar C, Elmberger G, Sandgren P, Skold CM, Eklund A. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. Eur Respir J 1998; 12: 595-600.
60. Lensmar C, Elmberger G, Skold M, Eklund A. Smoking alters the phenotype of macrophages in induced sputum. Respir Med 1998; 92: 415-20.
61. Domagała-Kulawik J, Maskey-Warzechowska M, Hermanowicz-Salamon J, Chazan R. Expression of macrophage surface markers in induced sputum of patients with COPD. J Physiol Pharamcol 2006 57: 75-85.
62. Domagala- Kulawik J, Maskey- Warzechowska M, Kraszewska I, Chazan R. The cellular composition and macrophage phenotype in induced sputum in smokers and ex-smokers with COPD. Chest 2003; 123: 1054-59.
63. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002; 121: 156S-9S.
64. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084-106.
65. Pons AR, Sauleda J, Noguera A, et al. Decreased macrophage release of TGF-beta and TIMP-1 in chronic obstructive pulmonary disease. Eur Respir J 2005; 26: 60-6.
66. Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur Respir J 2001; 17: 122-32.
67. Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest 2003; 124: 1199-205.
68. Yassallo R, Tamada R, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leadinf to preferential induction of Th2 priming. J Immunol 2005; 175: 2684-2691.
69. Craig PJ, Wells AU, Doffman S, et al. Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology 2004; 45, 275-282.
70. Peros-Golubicic T, Ljubic S. Cigarette smoking and sarcoidosis. Acta Med Croatica 1995; 49: 187-93.
71. Domagala-Kulawik J, Dabrowska M, Lesinski J, Chazan R. Expression of Fas antigen on BALF cells in sarcoidosis: differences between smokers and nonsmokers. Eur Respir J 2003; 22: 177S.
72. Aoshiba K, Tamaoki J, Nagai A. Acute cigarette smoke exposure induces apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1392-L1401.
73. Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest 2001; 31: 550-553.
74. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005; 25: 447-454.
75. Hoser G, Wasilewska D, Domagala-Kulawik J. Expression of Fas receptor on peripheral blood lymphocytes from patients with non-small cell lung cancer. Folia Histochem Cytobiol 2004; 42: 249-52.
76. Domagała-Kulawik J, Hoser G, Dabrowska M, Chazan R. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med 2006; in press
77. Frish SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1992; 124: 27-38.
78. Hodge SJ, Hodge GL, Holmes M, Reynolds PN. Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary disease. Cytometry B Clin Cytom 2004; 61: 27-34.
79. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001; 17: 946-53.
80. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-826.
81. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002; 121: 160S-5S.
82. Stockley RA Neutrophils and the pathogenesis of COPD. Chest 2002; 121: 151S-155S
83. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629-36.
84. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120(6):1917-22.
85. Cosio MG, Guerassimov A. Chronic obstructive pulmónary disease. Inflammation of small airways and lung parenchyma. Am J Respir Crit Care Med 1999; 160: S21-5.
86. de Jong JW, Belt-Gritter B, Koeter GH, Postma DS. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir Med 1997; 91: 67-76.
87. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005; 6: 38.
88. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 512-16.
89. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990; 141: S169-S202.
90. Saetta M, Finkelstein R, Cosio MG. Morphological and cellular basis for airflow limitation in smokers. Eur Respir J 1994; 7: 1505-15.
91. Hoser G, Kawiak J, Domagala-Kulawik J, Kopinski P, Droszcz W. Flow cytometric evaluation of lymphocyte subpopulations in BALF of healthy smokers and nonsmokers. Folia Histochem Cytobiol 1999; 37: 25-30.
92. Costabel U, Bross KJ, Reuter C, Ruhle KH, Matthys H. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986; 90: 39-44.
93. Korn S, Wiewrodt R, Walz YC, et al. Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in cigarette smokers. Am J Respir Cell Mol Biol 2005; 32: 142-8.
94. D'hulst KR, Bracke T, Maes JL, et al. Role of tumour necrosis factor-α receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema Eur Respir J 2006; 28: 102-112.
95. Sullivan A K, Simonian PL, Falta MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005; 172: 590-596.
96. Piazza CM, Gilardini S, Montani S, Moretti S, Cundari E, Piccolella E. Cutting edge: CD4+ T cells kill CD8+ T cells via Fas/Fas ligand-mediated apoptosis. J Immunol 1997; 158: 1503-1506.
97. Tateyama M, Oyaizu N, McCloskey TW, Than S, Pahwa S. CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas/FasL death signaling pathway. Blood 2000; 96: 195-202.
98. Glader P, von Wachenfeldt K, Lofdahl CG. Systemic CD4+ T-cell activation is correlated with FEV1 in smokers. Respir Med 2006; 100(6): 1088-93.
99. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis 1989; 139: 194-98.
100. Bosken CH, Hards J, Gatter K, Hogg JC. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis 1992; 145: 911-17.
101. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
102. Ginns LC, Goldenheim PD, Miller LG, et al. T-lympbocyte subsets in smoking and lung cancer: Analysis of monoclonal antibodies and flow cytometry. Am Rev Respir Dis 1982; 126: 265-69.
103. Ancochea J, Gonzalez A, Sanchez MJ, Aspa J, Lopez-Botet M. Expression of lymphocyte activation surface antigens in bronchoalveolar lavage and peripheral blood cells from young healthy subjects. Chest 1993; 104: 32-37.
104. Tollerud DJ, Clark JW, Brown LM, et al. The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. Am Rev Respir Dis 1989; 139: 1446-51.
105. Tanigawa T, Araki S, Nakata A, Sakurai S. Increase in the helper inducer (CD4+CD29+) T lymphocytes in smokers. Ind Health 1998; 36: 78-81.
106. Tollerud DJ, Brown LM, Blattner WA, et al. T cell subsets in healthy black smokers and nonsmokers. Evidence for ethnic group as an important response modifier. Am Rev Respir Dis 1991; 144: 612-16.
107. Tollerud DJ, Brown LM, Blattner WA, et al. Racial differences in serum immunoglobulin levels: relationship to cigarette smoking, T-cell subsets, and soluble interleukin-2 receptors. J Clin Lab Anal 1995; 9: 37-41.
108. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
109. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological study. Eur Respir J 2003; 22: 2s-4s
110. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46: 5s-13s.
111. Kim WD, Kim WS, Koh Y, et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 2002; 122: 437-44.
112. Yasuda N, Gotoh K, Minatoguchi S, et al. An increase of soluble Fas an inhibitor of apoptosis associated with progression of COPD. Respir Med 1998; 92: 993-999.
113. Varadhachary AS, Salgame P. CD95 mediated T cell apoptosis and its relevance to immune deviation. Oncogene 1998; 17: 3271-3276.
114. Kawiak J, Hoser G, Skorski T. Apoptosis and some of its medical implications. Folia Histochem Cytobiol 1998; 36: 99-110.
115. Mac Callum PK. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005; 2: 34-43.
116. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 44-9.
117. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006, 7: 70
118. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest 2002; 121: 127S-130S
119. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28(1): 219-42.
120. Moodie FM, Marwick JA, Anderson CS, et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J 2004; 18(15): 1897-9.
121. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 41-50.
122. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-90.
123. Godtfredsen NS, Vestbo J, Oster M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002; 57: 967-72.
124. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Timens W, Postma DS. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J. 2004; 24: 391-96.
125. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778-85.
126. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-76.
127. Scold CM, Hed J, Eklund A. Smoking cessation rapidly reduces cell recovery in bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high. Chest 1992; 101: 989-95.
128. Ind PW. COPD disease progression and airway inflammation: uncoupled by smoking cessation. Eur Respir J 2005; 26: 764-66.
129. Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease. Respir Res 2006; 7: 130.
130. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262-67.
131. Pankowska M, Duranska P. Domagala-Kulawik J, Chazan R. The impact of smoking cessation on respiratory symptoms in patients with COPD. Eur Respir J 2005; 26: 191S.